Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
60 DEGREES PHARMACEUTICALS LLC (SXTP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.94-7.18%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SXTP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
reduce EPS losses from -$3.45 in FY26 toward breakeven | A primary condition in 60 DEGREES PHARMACEUTICALS LLC's published investment case. The stated target is EPS loss less negative than -$3.45 in FY26. | Broken | EPS loss worsens beyond -$3.45 in FY26 | Diluted EPS: $-0.90 per share FY2026-Q2; GAAP. Published target: EPS loss less negative than -$3.45 in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-0.9 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making healthcare company, not an established earnings compounder. The thesis is in a watch state: clinical and regulatory work is continuing, but recent performance trails its industry cohort and the overall signal has shifted to mixed.
The valuation model describes SXTP as cheap versus peers, while also showing a small premium to peers and low confidence in that assessment. The priced-in tag is justified, with no fragility gates triggered, but the negative expectations gap and continuing losses leave little evidence that the apparent discount reflects a proven financial recovery.
Near term, earnings risk is elevated, and erratic surprises raise the chance of a miss; a guidance cut would add pressure to execution. Revenue was lower in 2026-Q2 than in 2025-Q4, while the operating loss widened across the reported periods, despite progress on tafenoquine development and regulatory work. The 2028 profitability objective remains stated, but the supplied results show limited progress toward it.
The multi-year view hinges on whether tafenoquine development and FDA engagement produce meaningful regulatory progress, and whether commercial growth can narrow operating losses. Near term, guidance, employment data, and results from healthcare bellwethers are key swing factors; the supplied evidence also reports recent litigation filings without further detail.
Over the next 1 to 3 years, SXTP remains a fragile, execution-dependent thesis: clinical progress is reported, but losses, weak recent financial delivery, and elevated near-term risk are unresolved. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
resolve ongoing litigation without major financial impact | A supporting condition in 60 DEGREES PHARMACEUTICALS LLC's published investment case. The stated target is no material negative impact from litigation. | Intact | litigation results in material financial loss or delays | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
achieve ~37% revenue growth to $900 million in FY26 | A primary condition in 60 DEGREES PHARMACEUTICALS LLC's published investment case. The stated target is >= $900 million revenue in FY26. | Intact | revenue falls below $900 million in FY26 | Revenue: $207,898 FY2026-Q2; GAAP. Published target: >= $900 million revenue in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026207,898 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.14 → $-3.58 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-07-25 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-07-26 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-07-27 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-07-28 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-07-29 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-07-30 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-07-31 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-08-01 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-02 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-08-03 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-04 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-05 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-06 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-08-08 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-09 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-08-10 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-08-12 | $-3.58 | $1,600,000 | 1 / 2 |
| 2026-08-13 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-14 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-15 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-16 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-17 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-18 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-19 | $-2.14 | $1,600,000 | 1 / 2 |
| 2026-08-20 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-21 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-22 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-23 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-24 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-25 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-26 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-27 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-28 | $-2.14 | $1,700,000 | 1 / 2 |
| 2026-08-29 | $-3.58 | $1,700,000 | 1 / 2 |
| 2026-08-30 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-08-31 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-01 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-02 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-03 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-04 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-05 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-06 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-07 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-08 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-09 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-10 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-11 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-12 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-13 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-14 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-15 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-16 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-17 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-18 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-19 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-20 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-21 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-22 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-23 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-24 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-25 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-26 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-27 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-28 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-29 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-09-30 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-01 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-02 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-03 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-04 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-05 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-06 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-07 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-08 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-09 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-10 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-11 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-12 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-13 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-14 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-15 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-16 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-17 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-18 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-19 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-20 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-21 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-22 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-23 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-24 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-25 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-26 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-27 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-28 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-29 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-30 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-10-31 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-11-01 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-11-02 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-11-03 | $-3.58 | $1,400,000 | 1 / 2 |
| 2026-11-04 | $-3.58 | $1,400,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.